BI 456906

12/01/2022 - "BI 456906 is a potent GCGR/GLP-1R dual agonist with robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake."
12/01/2022 - "BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy."
01/01/2023 - "BI 456906 showed no unexpected tolerability concerns and it reduced placebo-corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment."
01/01/2023 - "BI 456906 produced a placebo-corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity."
06/15/2023 - "Development of poly-agonists mimicking oxyntomodulin, such as the novel dual GCGR/GLP-1R agonist BI 456906, represents an important step towards a more effective treatment for people with Type 2 diabetes mellitus and obesity. "

01/01/2023 - "In the SRD study (N = 24), mean body weight decreased with increasing BI 456906 dose. "
01/01/2023 - "BI 456906 produced a placebo-corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity."
06/15/2023 - "Glucose-lowering efficacy of BI 456906 has been demonstrated in a Phase II trial in patients with Type 2 diabetes mellitus and obesity and was associated with clinically meaningful body weight loss. "

06/15/2023 - "Development of poly-agonists mimicking oxyntomodulin, such as the novel dual GCGR/GLP-1R agonist BI 456906, represents an important step towards a more effective treatment for people with Type 2 diabetes mellitus and obesity. "
06/15/2023 - "Glucose-lowering efficacy of BI 456906 has been demonstrated in a Phase II trial in patients with Type 2 diabetes mellitus and obesity and was associated with clinically meaningful body weight loss. "

01/01/2023 - "BI 456906 showed no unexpected tolerability concerns and it reduced placebo-corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment."
01/01/2023 - "BI 456906 produced a placebo-corrected body weight loss of 13.8% (week 16), highlighting its potential to promote clinically meaningful body weight loss in people with overweight/obesity."
01/01/2023 - "To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity. "
01/01/2023 - "A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity."
01/01/2023 - "To report two phase I studies of the novel subcutaneous glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) dual agonist BI 456906 versus placebo in healthy volunteers and people with overweight/obesity. "

01/01/2023 - "During MRD Part A (N = 80), 10 subjects (12.5%) discontinued BI 456906, most commonly because of a cardiac or vascular AE (n = 6, 7.5%); during Part B (N = 45), eight subjects (17.8%) discontinued BI 456906, mainly because of AEs (n = 6, 13.3%), most commonly gastrointestinal disorders. "